Advances in the Development of Amorphous Solid Dispersions: The Role of Polymeric Carriers

Overview

Journal Asian J Pharm Sci

Date 2023 Aug 28

PMID 37635801

Authors

Jie Zhang

Minshan Guo

Minqian Luo

Ting Cai

Affiliations

Soon will be listed here.

Abstract

Amorphous solid dispersion (ASD) is one of the most effective approaches for delivering poorly soluble drugs. In ASDs, polymeric materials serve as the carriers in which the drugs are dispersed at the molecular level. To prepare the solid dispersions, there are many polymers with various physicochemical and thermochemical characteristics available for use in ASD formulations. Polymer selection is of great importance because it influences the stability, solubility and dissolution rates, manufacturing process, and bioavailability of the ASD. This review article provides a comprehensive overview of ASDs from the perspectives of physicochemical characteristics of polymers, formulation designs and preparation methods. Furthermore, considerations of safety and regulatory requirements along with the studies recommended for characterizing and evaluating polymeric carriers are briefly discussed.

Citing Articles

Integrating In Vitro Dissolution and Physiologically Based Pharmacokinetic Modeling for Generic Drug Development: Evaluation of Amorphous Solid Dispersion Formulations for Tacrolimus.

Karakitsios E, Angelerou M, Kapralos I, Tsakiridou G, Kalantzi L, Dokoumetzidis A Pharmaceutics. 2025; 17(2).

PMID: 40006594 PMC: 11858865. DOI: 10.3390/pharmaceutics17020227.

3D-Printed Tablets of Nifurtimox: In Vitro and In Vivo Anti- Studies.

Bedogni G, Lima A, Gross I, Menezes T, Talvani A, Cunha-Filho M Pharmaceutics. 2025; 17(1.

PMID: 39861728 PMC: 11768318. DOI: 10.3390/pharmaceutics17010080.

Application of the Box-Behnken Design in the Development of Amorphous PVP K30-Phosphatidylcholine Dispersions for the Co-Delivery of Curcumin and Hesperetin Prepared by Hot-Melt Extrusion.

Wdowiak K, Tajber L, Miklaszewski A, Cielecka-Piontek J Pharmaceutics. 2025; 17(1).

PMID: 39861675 PMC: 11768460. DOI: 10.3390/pharmaceutics17010026.

Pediatric Formulation Optimization Using a Rational Design: Exploring Amorphous Solid Dispersion Technology with Terbinafine Hydrochloride as a Case Study.

Boza I, da Silva S, Guedes N, Bazzo G, Stulzer H AAPS PharmSciTech. 2025; 26(1):40.

PMID: 39821556 DOI: 10.1208/s12249-024-03012-4.

A drug-drug co-amorphous system for highly improved solubility of breviscapine: an experimental and computational study.

Dong Z, Jin W, Wang J, Yin H, Ma Y, Hu X Sci Rep. 2024; 14(1):31183.

PMID: 39732994 PMC: 11682056. DOI: 10.1038/s41598-024-82524-2.

References

Shi Q, Zhang C, Su Y, Zhang J, Zhou D, Cai T . Acceleration of Crystal Growth of Amorphous Griseofulvin by Low-Concentration Poly(ethylene oxide): Aspects of Crystallization Kinetics and Molecular Mobility. Mol Pharm. 2017; 14(7):2262-2272. DOI: 10.1021/acs.molpharmaceut.7b00097. View

Ueda K, Okada H, Zhao Z, Higashi K, Moribe K . Application of solid-state C relaxation time to prediction of the recrystallization inhibition strength of polymers on amorphous felodipine at low polymer loading. Int J Pharm. 2020; 581:119300. DOI: 10.1016/j.ijpharm.2020.119300. View

Zeng Y, Li S, Liu C, Gong T, Sun X, Fu Y . Soluplus micelles for improving the oral bioavailability of scopoletin and their hypouricemic effect in vivo. Acta Pharmacol Sin. 2017; 38(3):424-433. PMC: 5342662. DOI: 10.1038/aps.2016.126. View

Goddeeris C, Willems T, Van den Mooter G . Formulation of fast disintegrating tablets of ternary solid dispersions consisting of TPGS 1000 and HPMC 2910 or PVPVA 64 to improve the dissolution of the anti-HIV drug UC 781. Eur J Pharm Sci. 2008; 34(4-5):293-302. DOI: 10.1016/j.ejps.2008.05.005. View

Schittny A, Huwyler J, Puchkov M . Mechanisms of increased bioavailability through amorphous solid dispersions: a review. Drug Deliv. 2019; 27(1):110-127. PMC: 6968646. DOI: 10.1080/10717544.2019.1704940. View

Moseson D, Corum I, Lust A, Altman K, Hiew T, Eren A . Amorphous Solid Dispersions Containing Residual Crystallinity: Competition Between Dissolution and Matrix Crystallization. AAPS J. 2021; 23(4):69. DOI: 10.1208/s12248-021-00598-6. View

Saraf I, Roskar R, Modhave D, Brunsteiner M, Karn A, Neshchadin D . Forced Solid-State Oxidation Studies of Nifedipine-PVP Amorphous Solid Dispersion. Mol Pharm. 2022; 19(2):568-583. DOI: 10.1021/acs.molpharmaceut.1c00678. View

Song Y, Yang X, Chen X, Nie H, Byrn S, Lubach J . Investigation of drug-excipient interactions in lapatinib amorphous solid dispersions using solid-state NMR spectroscopy. Mol Pharm. 2015; 12(3):857-66. DOI: 10.1021/mp500692a. View

Sathigari S, Radhakrishnan V, Davis V, Parsons D, Jayachandra Babu R . Amorphous-state characterization of efavirenz--polymer hot-melt extrusion systems for dissolution enhancement. J Pharm Sci. 2012; 101(9):3456-64. DOI: 10.1002/jps.23125. View

10.

Correa-Soto C, Gao Y, Indulkar A, Zhang G, Taylor L . Role of surfactants in improving release from higher drug loading amorphous solid dispersions. Int J Pharm. 2022; 625:122120. DOI: 10.1016/j.ijpharm.2022.122120. View

11.

Knopp M, Tajber L, Tian Y, Olesen N, Jones D, Kozyra A . Comparative Study of Different Methods for the Prediction of Drug-Polymer Solubility. Mol Pharm. 2015; 12(9):3408-19. DOI: 10.1021/acs.molpharmaceut.5b00423. View

12.

Xu H, Vela S, Shi Y, Marroum P, Gao P . In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. Mol Pharm. 2017; 14(11):3801-3814. DOI: 10.1021/acs.molpharmaceut.7b00552. View

13.

Lang M, Grzesiak A, Matzger A . The use of polymer heteronuclei for crystalline polymorph selection. J Am Chem Soc. 2002; 124(50):14834-5. DOI: 10.1021/ja0286526. View

14.

Huang C, Chen Z, Gui Y, Shi C, Zhang G, Yu L . Crystal nucleation rates in glass-forming molecular liquids: D-sorbitol, D-arabitol, D-xylitol, and glycerol. J Chem Phys. 2018; 149(5):054503. DOI: 10.1063/1.5042112. View

15.

Vasconcelos T, Marques S, das Neves J, Sarmento B . Amorphous solid dispersions: Rational selection of a manufacturing process. Adv Drug Deliv Rev. 2016; 100:85-101. DOI: 10.1016/j.addr.2016.01.012. View

16.

Yao X, Kim S, Gui Y, Chen Z, Yu J, Jones K . Amorphous Drug-Polymer Salt with High Stability under Tropical Conditions and Fast Dissolution: The Challenging Case of Lumefantrine-PAA. J Pharm Sci. 2021; 110(11):3670-3677. DOI: 10.1016/j.xphs.2021.07.018. View

17.

Van Duong T, Van den Mooter G . The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers. Expert Opin Drug Deliv. 2016; 13(12):1681-1694. DOI: 10.1080/17425247.2016.1198769. View

18.

Santitewagun S, Thakkar R, Zeitler J, Maniruzzaman M . Detecting Crystallinity Using Terahertz Spectroscopy in 3D Printed Amorphous Solid Dispersions. Mol Pharm. 2022; 19(7):2380-2389. DOI: 10.1021/acs.molpharmaceut.2c00163. View

19.

Karekar P, Vyas V, Shah M, Sancheti P, Pore Y . Physicochemical investigation of the solid dispersion systems of etoricoxib with poloxamer 188. Pharm Dev Technol. 2009; 14(4):373-9. DOI: 10.1080/10837450802683974. View

20.

Lubach J, Hau J . Solid-State NMR Investigation of Drug-Excipient Interactions and Phase Behavior in Indomethacin-Eudragit E Amorphous Solid Dispersions. Pharm Res. 2018; 35(3):65. DOI: 10.1007/s11095-018-2364-y. View